Lilly Gets a Lift from Zyprexa News

The drugmaker expects to pay less than $500 million to settle lawsuits connected with the anti-psychotic compound

Eli Lilly (LLY) expects to settle thousands of lawsuits over how it marketed the anti-psychotic drug Zyprexa for less than $500 million, the Indianapolis pharmaceutical company said on Jan. 4.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.